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Abstract 
Background: Whereas a few studies have reported associations of serum omentin levels with subclinical atheroscle‑
rosis in patients with diabetes, little information is available with respect to the associations of serum omentin levels 
and diabetic microvascular complications. The aim of this study was to investigate the relationships of serum omentin 
levels and vascular complications including cardiac autonomic neuropathy (CAN) in patients with type 2 diabetes 
mellitus (T2DM).
Methods: We recruited 97 patients who evaluated complications of diabetes. CAN was assessed by five standard 
cardiovascular reflex tests according to Ewing’s protocol. Diabetic nephropathy (DN), retinopathy (DR), and peripheral 
neuropathy (DPN) were evaluated. Serum omentin levels were assessed by ELISA. Atherosclerotic burden was evalu‑
ated by measuring the brachial‑ankle pulse wave velocity (baPWV) and ankle brachial index (ABI).
Results: The prevalence of CAN increased borderline significantly across the omentin tertiles (p = 0.05) and CAN 
point increased significantly and progressively across the omentin tertiles (p = 0.013). The prevalence of other 
microvascular complications (DPN, DN, and DR) did not differ among omentin tertiles. The mean levels of baPWV also 
increased significantly and progressively across the omentin tertiles (p = 0.002). Serum omentin levels were signifi‑
cantly positively correlated with CAN point (p = 0.004) and borderline significantly correlated with baPWV (p = 0.05) 
after multivariate adjustment. Regarding linear regression analysis for CAN point, univariate regression analysis 
demonstrated that CAN point associated with omentin, diastolic blood pressure (DBP) and hsCRP. Multiple regression 
analysis revealed that omentin levels, together DBP and baPWV correlated with CAN point. This present study sug‑
gests that serum omentin levels may be independently associate with CAN in patients with T2DM.
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Background
It has been hypothesized that diabetic microvascular and 
macrovascular complications have common pathogene-
ses. Insulin resistance or adipocytokines may be common 
underlying causes of diabetes vascular complications [1]. 
Moreover, adipose tissue dysfunction and an altered fat 
distribution might be involved in insulin resistance and 
atherosclerosis [2].
Omentin is a protein composed of 313 aminoacids, 
which is produced exclusively in the stromal cells of vis-
ceral adipose tissue [3, 4]. The known effects of omentin 
include insulin-sensitizing and, anti-inflammatory activi-
ties beneficial to vascular health. In several clinical stud-
ies, serum levels of omentin were reported to be reduced 
during dysmetabolic states [5–7]. Serum omentin levels 
Open Access
*Correspondence:  hanna@schmc.ac.kr 
†Chan‑Hee Jung and Sang‑Hee Jung have contributed equally to the 
work and both should be considered as first authors
1 Division of Endocrinology and Metabolism, Department of Internal 
Medicine, Soonchunhyang University College of Medicine, #170 
Jomaru‑ro, Wonmi‑gu, Bucheon‑si, Gyeonggi‑do 420‑767, Republic 
of Korea
Full list of author information is available at the end of the article
Page 2 of 9Jung et al. Cardiovasc Diabetol  (2015) 14:140 
also are negatively correlated with BMI, metabolic risk 
factors and inflammatory markers, and positively cor-
related with serum adiponectin and high density lipo-
protein-cholesterol (HDL-C) levels [8–11]. However, 
contradictory results also have been reported regarding 
the association of serum omentin with the above-men-
tioned metabolic risk factors [12, 13].
One of the most overlooked of all of the complications 
of diabetes is cardiac autonomic neuropathy (CAN), 
which is a significant cause of morbidity and mortality 
in patients with diabetes [14, 15]. Although the mecha-
nisms by which CAN leads to increased mortality remain 
unclear, poor glycemic control, duration of diabetes and 
other cardiovascular disease (CVD) risk factors such as 
hypertension and smoking play key roles in the devel-
opment and severity of CAN. However, strict control of 
these risk factors does not abolish the risk of CAN, sug-
gesting that other factors that contribute to CAN are yet 
to be identified [16, 17].
Whereas a few studies have reported associations of 
serum omentin levels with carotid atherosclerosis or 
arterial stiffness as an index of subclinical atherosclero-
sis in patients with diabetes, very few studies have inves-
tigated the associations of serum omentin levels with 
microvascular complications. Moreover, to our knowl-
edge, no study has investigated the relationship between 
serum omentin and CAN in patients with T2DM.
Therefore, in the present study, we examined the rela-
tionship among serum omentin levels, subclinical ath-
erosclerosis markers, and microvascular complications 
including CAN in patients with T2DM.
Methods
Patients
We recruited 146 patients with diabetes who were evalu-
ated for microvascular complications at the diabetes 
clinic of Soonchunhyang University Bucheon Hospital 
from April 2012 to February 2014. Among them, those 
with type 1 diabetes, and those with severe illness, such 
as heart failure, liver cirrhosis with ascites, severe infec-
tion, malignancy, uncontrolled hyperthyroidism or a 
history of arrhythmia, and were not available fasting 
serum samples or clinical data from medical records 
were excluded. Finally, this study included 97 patients 
with T2DM (men 56, women 41, mean age: 57.6 years). 
We reviewed detailed demographic data, biochemical 
data, and clinical and treatment histories from patient 
medical records. The smoking status of the subjects was 
classified as being a non-smokers or smokers (former or 
current). All patients were informed of the purpose of the 
study and written consent was obtained. The study was 
approved by the Institutional Review Board of Soonchun-
hyang University School of Medicine, Bucheon Hospital.
Measurement of serum omentin
Blood samples were taken after overnight fasting. Serum 
was separated and stored at −80  °C until analyzed. 
Serum omentin levels were measured using a commer-
cially available enzyme-linked immunosorbent assay 
(ELISA; R&D Systems, Minneapolis, MN, USA). Serum 
insulin and C-peptide levels were measured by radioim-
munoassay (Immunotech, Prague, Czech Republic).
Cardiac autonomic neuropathy and microvascular 
complications
CAN was assessed by an autonomic function test 
(AFT). CAN was assessed by five standard cardiovascu-
lar reflex tests according to Ewing’s protocol [18]. The 
patients were asked to fast for 12 h before the test, and to 
avoid taking antihypertensive agent such as beta-blocker, 
caffeine, nicotine, or antihistamines. Three of these meas-
urements mainly assess parasympathetic function : heart 
rate responses to deep breathing (beat-to-beat variation), 
to standing (30:15 ratio), and to the Valsalva maneuver. 
The other two tests mainly assess sympathetic function: 
blood pressure responses to standing and to a sustained 
handgrip. The heart rate response to deep breathing, 
standing, and the Valsalva maneuver were assessed auto-
matically from ECG recordings using the DICAN evalu-
ation system (Medicore Co. Ltd, Korea). The results of 
each of the above five tests for the detection of CAN were 
classified into one of three categories based on the sever-
ity of abnormality detected, and each of them was given 
a definite point value as described by Bellavere et al. [19]. 
The severity of CAN was quantified from the summation 
of the points obtained from each of the five tests, where 
each test was given a point value of 0, 0.5, or 1 if it yielded 
normal, borderline, or abnormal values, respectively. 
Consequently, the minimum and maximum numbers of 
autonomic neuropathy points were 0 and 5, respectively. 
CAN was defined as the presence of at least two abnor-
mal tests or an autonomic neuropathy points total ≥2.
Diabetic nephropathy (DN) was defined using albu-
minuria, which was measured by radioimmunoassay 
(Immunotech). An albumin excretion rate (AER) <20 μg/
min or urine albumin <30 mg/g creatinine were the cri-
teria for normoalbuminuria; an AER in the range of 
20–200  μg/min or urine albumin 30–300  mg/g creati-
nine, microalbuminuria; and an AER ≥200  μg/min or 
urine albumin ≥300 mg/g creatinine as overt proteinuria. 
Patients were considered to have nephropathy if they had 
microalbuminuria or overt proteinuria.
Diabetic retinopathy (DR) was evaluated by experi-
enced ophthalmologists while the patients’ pupils were 
dilated. If needed, fluorescein angiography was per-
formed. Patients were classified as normal, or as having 
non-proliferative or proliferative retinopathy; patients 
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were considered to have retinopathy if they were in the 
non-proliferative or proliferative stage.
Diabetic peripheral neuropathy (DPN) was diag-
nosed in subjects displaying two or more of the follow-
ing features: typical subjective neuropathic symptoms 
determined using the Michigan Neuropathy Screening 
Instrument (MNSI), insensitivity to a 10-g monofilament, 
abnormal pin-prick sensation, and abnormal current per-
ception threshold (CPT), or a nerve conduction study. 
CPT was performed with a Neurometer CPT/C (Neuro-
tron, Inc., Baltimore, MD, USA).
An automated device (VP-1000; Colin, Japan) was used 
to measure arterial PWV and the ABI. Insulin resistance 
status was evaluated by the homeostasis model assess-
ment-insulin resistance (HOMA-IR) index. The HOMA-
IR was calculated using the formulae: [fasting insulin 
(uIU/mL) × fasting blood glucose (mmol/L)]/22.5. The 
HOMA-IR score was available in only 89 patients not 
receiving exogenous insulin.
Statistical analysis
Statistical analysis was performed using SPSS 14.0 
(SPSS Inc, Chicago, IL, USA). Data are reported as 
mean ± standard deviation (SD) for normally distributed 
variables, as median (interquartile range) for non-nor-
mally distributed variables or as number of participants 
(percentages). Statistical differences in demographic and 
clinical characteristics between groups by gender were 
evaluated by means of Chi square test or Fisher’s exact 
test for categorical variables and Student’s t test or Wil-
coxon’s ranksum test for continuous variables. Before 
the t test, Shapiro–Wilk test for normality and Levene’s 
homogeneity of variance test was conducted. Non-
normally distributed variables, that is, omentin, hsCRP, 
triglyceride and HOMA-IR, were natural-logarithm-
transformed before analysis. The significance of the mean 
differences in parameters among the tertiles of omentin 
levels was evaluated with one-way ANOVA. Post-hoc 
comparison for tertiles of omentin groups was performed 
with the adjusted p-value using Tukey’s HSD method.
The correlation of serum omentin levels and other clin-
ical variables was assessed by Pearson’s correlation coef-
ficient or Spearman’s rank correlation as appropriate. In 
addition, partial correlations were computed after adjust-
ment for age, mean PWV, and CAN points. To determine 
the particular aspects of anthropometric, biochemical, 
and metabolic parameters that are related to CAN point, 
simple linear regression was conducted for each explana-
tory variable. On the result of simple linear regression, 
multiple linear regression analyses were performed to 
check the original relationship of each variable and CAN 
point when the other variables were adjusted. The signifi-
cance of the relationship between CAN point and each 
explanatory variable was evaluated with a t-test for each 
regression coefficient. An F test was used to test the sig-
nificance of the proportion of variance in CAN point (R2) 
that was explained in the model, the regression model 
which included the subset of explanatory variables that 
were at least marginally significant (p < 0.15).
Results
Clinical characteristics of the participants
The 97 patients consisted of 56 men and 41 women; their 
anthropometric parameters, clinical characteristics, and 
omentin levels are presented in Table 1. The mean age of 
the total participants was 57.6 years, and the mean dura-
tion of diabetes was 9.1 years. The mean body mass index 
(BMI) was 24.8  kg/m2. The mean level of serum omen-
tin was 530  ±  302  ng/mL and did not differ between 
men and women. Only one man was treated with beta-
blocker and the prevalence of prescribed medication of 
beta-blocker was not different between men and women. 
Of the 97 patients, 38 (42.2  %) were defined as having 
DPN and 30 (36.6  %) as having CAN. The prevalence 
of DN was 12 (13.3 %) and the prevalence of DR was 27 
(30 %). The prevalence of DPN was higher in women than 
in men (56.8 vs. 32.1 %, p =  0.034). Regarding the lipid 
profile, higher total cholesterol and HDL-C and lower tri-
glyceride were found in women than in men.
Comparisons of clinical variables according to the tertiles 
of omentin levels
The participants were divided into three groups accord-
ing to serum omentin levels. The clinical parameters 
according to the omentin tertile are shown in Table  2. 
The baPWV representing arterial stiffness significantly 
increased as the levels of omentin increased across the 
tertiles (1381 vs. 1490 vs. 1605  cm/s, p  =  0.002). The 
mean values of anthropometric indices and metabolic 
variables such as blood glucose and lipid profile except 
total cholesterol did not differ significantly among omen-
tin tertiles. There were no significant differences in the 
prevalence of ACEI, ARB or statin intake among the 
serum omentin tertiles. The prevalence of CAN showed 
an increasing trend across omentin tertiles (20.7 vs. 39.3 
vs. 52 %, p = 0.05, p for trend = 0.017) and CAN points 
increased significantly and progressively across the 
omentin tertiles (p = 0.013) (Table 2).
The prevalence of other microvascular complications 
(DPN, DN, and DR) did not differ among omentin ter-
tiles. In addition, mean serum omentin levels did not dif-
fer significantly depending on the presence or absence 
of microvascular complications (regarding DPN, 496 vs. 
559 ng/mL, p = 0.346; regarding DR, 474 vs. 551 ng/mL, 
p =  0.28; regarding DN, 582 vs 522  ng/mL, p =  0.535) 
(data not shown).
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Bivariate correlations between omentin and clinical 
parameters
The results of bivariate correlation analyses between 
serum omentin, baPWV, and various clinical param-
eters are shown in Table  3. Serum omentin lev-
els showed significant positive correlations with age 
(r = 0.3, p = 0.003), baPWV (r = 0.266, p = 0.009), and 
CAN points (r = 0.327, p = 0.003). HbA1C, hsCRP, and 
HOMA-IR were not correlated with omentin levels. Par-
tial correlation analysis after adjustment for age, mean 
baPWV, and CAN points revealed that serum omen-
tin levels were positively correlated with CAN points 
Table 1 General characteristics of the participants
Data are shown as mean ± SD, median (interquartile range) or as n (%)
DM diabetes mellitus, WC waist circumference, BP blood pressure, HbA1C hemoglobin A1C, FPG fasting plasma glucose, LDL low density lipoprotein, HDL high density 
lipoprotein, hsCRP high-sensitivity C-reactive protein, HOMA-IR homeostasis model assessment-insulin resistance, ABI ankle-brachial index, PWV pulse wave velocity, 
OHA oral hypoglycemic agent, DPN diabetic peripheral neuropathy, CAN cardiac autonomic neuropathy, DN diabetic nephropathy, DR diabetic retinopathy, OHA oral 
hypoglycemic agent, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker
Total (n = 97) Men (n = 56) Women (n = 41) p value
Anthropometric parameters
 Age 57.6 ± 8.2 56.7 ± 7.6 58.9 ± 8.9 0.181
 Duration of DM (years) 9.1 ± 6.0 9.4 ± 6.5 8.9 ± 5.4 0.875
 Body mass index (kg/m2) 24.8 ± 2.7 25.2 ± 2.2 24.3 ± 3.2 0.125
 WC (cm) 86.5 ± 8.6 87.9 ± 8.0 84.5 ± 9.2 0.185
 Hypertension, n (%) 39 (40.2 %) 23 (41.8 %) 16 (39 %) 0.948
 Systolic BP (mmHg) 122.8 ± 14.1 120.8 ± 10.0 125.5 ± 18.1 0.419
 Diastolic BP (mmHg) 74.9 ± 8.6 76.2 ± 8.6 73.2 ± 8.4 0.093
 Current smoking, n (%) 19 (20.2 %) 19 (34.6 %) 0 <0.001
 Alcohol intake, n (%) 30 (31.9 %) 27 (49.1 %) 3 (7.7 %) <0.001
Biochemical and metabolic parameters
 Omentin (ng/mL) 530 ± 302 527 ± 354 534 ± 214 0.375
 HbA1C (mmol/mol) (%) 55 (7.2) 53 (7) 57 (7.4) 0.128
 FPG (mmol/L) 7.4 ± 2.0 7.3 ± 1.8 7.5 ± 2.3 0.921
 Total cholesterol (mmol/L) 4.0 ± 0.7 3.9 ± 0.7 4.2 ± 0.7 0.015
 LDL‑cholesterol (mmol/L) 2.3 ± 0.6 2.2 ± 0.6 2.5 ± 0.6 0.061
 HDL‑cholesterol (mmol/L) 1.3 ± 0.3 1.2 ± 0.3 1.3 ± 0.3 0.021
 Triglycerides (mmol/L) 1.3 (0.8–1.9) 1.5 (1.0–2.0) 1.0 (0.7–1.8) 0.042
 hsCRP (mg/dL) 0.07 (0.05–0.12) 0.08 (0.05–0.12) 0.07 (0.05–0.13) 0.698
 Creatinine (μmol/L) 97 ± 115 97 ± 18 97 ± 168 0.861
 Urinary albumin (mg/g) 16.1 ± 27.4 16.3 ± 29.0 15.8 ± 25.6 0.351
 Insulin (fasting) (uIU/mL) 9.2 ± 4.9 8.9 ± 4.5 9.7 ± 5.4 0.628
 C‑peptide (fasting) (ng/mL) 2.2 ± 1.1 2.3 ± 0.9 2.2 ± 1.3 0.668
 HOMA‑IR 2.97 ± 1.62 2.80 ± 1.41 3.23 ± 1.87 0.506
 ABI 1.14 ± 0.11 1.12 ± 0.14 1.15 ± 0.05 0.280
 PWV (cm/s) 1493 ± 240 1480 ± 211 1511 ± 276 0.697
 DPN, n (%) 38 (42.2 %) 17 (32.1 %) 21 (56.8 %) 0.034
 CAN, n (%) 30 (36.6 %) 20 (40.1 %) 10 (30.3 %) 0.462
 Diabetic nephropathy, n (%) 12 (13.3 %) 7 (13.5 %) 5 (13.2 %) 0.925
 Diabetic retinopathy, n (%) 27 (30.0 %) 14 (26.4 %) 13 (35.1 %) 0.513
Treatment modality 0.135
 No medication, n (%) 4 (4.1) 4 (7.1 %) 0
 OHA, n (%) 85 (87.6) 50 (89.3 %) 35 (85.4 %)
 OHA + insulin, n (%) 5 (5.2) 2 (3.6 %) 3 (7.3 %)
 Insulin only, n (%) 3 (3.1) 0 3 (7.3 %)
 ACEI/ARB 32 (33 %) 20 (35.7 %) 12 (29 %) 0.654
 Beta‑blocker 1 (1.03 %) 1 (1.8 %) 0 0.691
 Statin 60 (62 %) 33 (58.9 %) 27 (65.9 %) 0.629
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(r = 0.31, p = 0.004) and borderline significantly corre-
lated with baPWV (r = 0.208, p = 0.05).
Regression analysis for CAN point
Result of regression analysis for CAN point is shown in 
Table  4. Univariate regression analysis for CAN point 
demonstrated that serum omentin and diastolic BP 
were positively correlated with CAN point and hsCRP 
was negatively correlated with CAN point. Multiple 
regression analysis revealed that serum omentin levels, 
together DBP and baPWV significantly associated with 
CAN point.
Discussion
In the present study, higher serum omentin levels were 
associated with a higher prevalence and severity of CAN 
in patients with T2DM. In addition, elevated serum 
omentin levels seemed to be associated with arterial stiff-
ness, as assessed by baPWV. On the other hand, there 
were no associations of serum omentin levels with the 
Table 2 The comparisons of clinical variables according to the tertile of omentin levels
Data are shown as mean ± SD, median (interquartile range) or as n (%)
DM diabetes mellitus, WC waist circumference, BP blood pressure, HbA1C hemoglobin A1C, FPG fasting plasma glucose, LDL low density lipoprotein, HDL high density 
lipoprotein, hsCRP high-sensitivity C-reactive protein, HOMA-IR homeostasis model assessment-insulin resistance, ABI ankle-brachial index, PWV pulse wave velocity, 
CAN cardiac autonomic neuropathy, DPN diabetic peripheral neuropathy, DN diabetic nephropathy, DR diabetic retinopathy, ACEI angiotensin converting enzyme 
inhibitor, ARB angiotensin receptor blocker
1st tertile 2nd tertile 3rd tertile P value (P for trend)
Omentin (ng/mL) 353 ± 36 459 ± 35 770 ± 418 <0.001
Age 54.8 ± 6.0 55.8 ± 8.3 62.1 ± 8.3 <0.001
Men/women 20/12 19/13 17/16 0.652
Duration of DM (years) 9.1 ± 5.7 9.9 ± 6.8 8.4 ± 5.5 0.779
Body mass index (kg/m2) 24.8 ± 2.7 25.6 ± 2.5 24.1 ± 2.8 0.071
WC (cm) 83.6 ± 8.6 88.1 ± 9.1 87.4 ± 8.0 0.160
Hypertension (%) 20/12(37.5) 19/13(40.6) 18/14(43.8) 0.878
Systolic BP (mmHg) 120.0 ± 13.9 121.9 ± 9.6 126.2 ± 17.6 0.209
Diastolic BP (mmHg) 75.3 ± 9.7 73.3 ± 7.1 76.1 ± 8.8 0.415
Current smoking, n (%) 7 (21.9) 7 (22.6) 5 (16.1) 0.785
Alcohol intake, n (%) 12 (37.5) 9 (29) 9 (29) 0.706
HbA1C (mmol/mol) (%) 53 (7) 56 (7.3) 54 (7.1) 0.652
FPG (mmol/L) 6.9 ± 1.1 8.0 ± 2.3 7.2 ± 2.2 0.070
Total cholesterol (mmol/L) 3.8 ± 0.5 4.2 ± 1.1 3.4 ± 1.0 0.051
LDL‑cholesterol (mmol/L) 2.2 ± 0.4 2.5 ± 0.7 2.3 ± 0.7 0.120
HDL‑cholesterol (mmol/L) 1.2 ± 0.3 1.3 ± 0.3 1.3 ± 0.3 0.144
Triglycerides (mmol/L) 1.3 (0.8–1.3) 1.3 (0.8–2.0) 1.2 (1.0–1.8) 0.786
hsCRP 0.07 (0.04–0.12) 0.09 (0.06–0.13) 0.07 (0.06–0.13) 0.359
Creatinine (μmol/L) 80 ± 9 124 ± 194 88 ± 27 0.648
Urinary albumin (mg/g) 9.2 ± 9.0 17.7 ± 27.9 21.8 ± 37.4 0.561
Insulin (fasting) (uIU/mL) 9.5 ± 4.8 9.9 ± 5.9 8.3 ± 3.7 0.558
c‑peptide (fasting) (ng/mL) 2.3 ± 1.2 2.3 ± 1.2 2.1 ± 0.9 0.705
HOMA‑IR 2.89 ± 1.45 3.45 ± 2.04 2.61 ± 1.26 0.293
ABI 1.13 ± 0.17 1.14 ± 0.05 1.14 ± 0.07 0.222
PWV (cm/s) 1381 ± 194 1490 ± 202 1605 ± 265 0.002 (p < 0.001)
CAN points 1.1 ± 0.8 1.3 ± 0.8 1.9 ± 1.3 0.013 (p = 0.003)
DPN, n (%) 13 (41.9) 15 (50) 10 (34.5) 0.483
CAN, n (%) 6 (20.7) 11 (39.3) 13 (52) 0.05 (p = 0.017)
DN, n (%) 1 (3.0) 6 (20) 5(17.2) 0.118 
DR, n (%) 10 (32.3) 10 (34.5) 7 (23.3) 0.610 
ACEI/ARB 7 (21.9) 13 (40.6) 12 (36.4) 0.246
Statin 17 (53.1) 21 (65.6) 22 (66.7) 0.461
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presence of other various microangiopathies (DPN, DN, 
and DR). To the best of our knowledge, this is the first 
report on the relationships of serum omentin level and all 
microvascular complications including CAN in patients 
with T2DM.
Omentin is an adipokine that is mainly expressed 
in visceral adipose tissue, and has been suggested as a 
biomarker of metabolic disorders [10]. Several studies 
have shown that serum omentin levels were negatively 
correlated with metabolic risk factors and seemed to 
have anti-inflammatory and insulin-sensitizing effects 
[8–10]. Moreover, omentin may play a protective role 
in the cardiovascular system due to its effects on vaso-
dilation, endothelial function and arterial calcification 
[20, 21]. These actions of omentin may be involved in 
the pathogenesis of atherosclerosis [22]. Zhong et  al. 
reported that serum omentin levels were lower in patients 
with coronary artery disease [23]. Analyses of serum 
omentin levels have been performed mainly in healthy 
subjects or those with obesity or metabolic syndrome, 
but rarely in patients with T2DM [24]. Until now, only a 
few studies have reported associations between omentin 
and subclinical atherosclerosis (e.g. carotid atherosclero-
sis) [12, 25]. However, little information is available with 
respect to the associations of serum omentin levels and 
diabetic microvascular complications. To the best of our 
knowledge, no study focusing on the association between 
Table 3 Correlation of  serum omentin levels and  other 
clinical variables
DM diabetes mellitus, WC waist circumference, BP blood pressure, HbA1C 
hemoglobin A1C, FPG fasting plasma glucose, LDL low density lipoprotein, HDL 
high density lipoprotein, hsCRP high-sensitivity C-reactive protein, HOMA-IR 
homeostasis model assessment-insulin resistance, ABI ankle-brachial index, PWV 
pulse wave velocity, CAN cardiac autonomic neuropathy
a Natural logarithmic transformations were performed before analysis
b Partial correlations were computed adjusted for age, mean PWV, and CAN 
points
Log-transformed omentin
Correlation (r) p value Partial  
correlation (r)b
p value
Age 0.3 0.003 0.158 0.156
Duration of DM 0.058 0.577
Body mass index −0.166 0.105
WC 0.088 0.455
Systolic BP 0.051 0.623
Diastolic BP −0.036 0.73
HbA1C 0.113 0.271
FPG 0.045 0.664














Mean ABI −0.029 0.78
Mean baPWV 0.266 0.009 0.208 0.050
CAN points 0.327 0.003 0.310 0.004
Table 4 Linear regression analysis for CAN point
CAN cardiac autonomic neuropathy, DM diabetes mellitus, WC waist 
circumference, BP blood pressure, HbA1C hemoglobin A1C, FPG fasting plasma 
glucose, LDL low density lipoprotein, HDL high density lipoprotein, hsCRP high-
sensitivity C-reactive protein, HOMA-IR homeostasis model assessment-insulin 
resistance, ABI ankle-brachial index, PWV pulse wave velocity, DPN diabetic 
peripheral neuropathy, DN diabetic nephropathy, DR diabetic retinopathy, ACEI 
angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker
R2  = 0.235; F = 5.682; P < 0.001
a Natural logarithmic transformations were performed before analysis
CAN point
Univariate Multivariate
Beta p value Beta p value
Omentina 0.66 0.027 0.61 0.048
Age 0.02 0.09
Duration of DM −0.02 0.241
Body mass index 0.02 0.664
WC 0.02 0.138
Systolic BP 0.01 0.068
Diastolic BP 0.03 0.013 0.04 0.009
HbA1C 0.01 0.950
FPG 0.00 0.415






Insulin (fasting) −0.01 0.693
C‑peptide (fasting) 0.03 0.781
Urinary microalbumin 0.00 0.867
HOMA‑IR −0.07 0.336
mean ABI −0.18 0.857
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omentin and microvascular complications has been pub-
lished so far. There is now convincing data demonstrating 
that common pathogenic mechanisms such as inflamma-
tion, oxidative stress and altered levels of adipocytokines 
are related to both microvascular and macrovascular 
complications [1]. Therefore, we investigated the rela-
tionship between omentin and microvascular complica-
tions including CAN.
We found that serum omentin levels did not differ 
between patients with and without each microvascular 
complication. Also, the prevalence of diabetic micro-
vascular complications (nephropathy, retinopathy and 
peripheral neuropathy) did not differ significantly among 
the omentin tertiles. However, the prevalence of CAN 
showed an increasing trend across the omentin tertiles, 
and CAN point increased significantly and progressively 
across the omentin tertiles.
CAN is a significant cause of morbidity and mortality 
in diabetic patients and is associated with a high risk of 
cardiac arrhythmia and sudden death, possibly related to 
silent myocardial ischemia [26, 27]. Few prior studies have 
reported associations between CAN and levels of adipo-
cytokines (leptin, adiponectin, TNF-alpha) [28]. Although 
it is not clear why serum omentin levels were positively 
correlated with the severity of CAN, contrary to the pre-
viously established anti-atherosclerotic and cardioprotec-
tive roles of omentin, some possible explanations can be 
suggested. One is that, in response to autonomic dysfunc-
tion promoted by endothelial dysfunction, inflammation, 
oxidative stress, and insulin resistance, the serum omentin 
level may be increased compensatorily. Generally, recent 
reports reported reduced omentin levels are related with 
cardiovascular and metabolic disease, whereas there 
are some different findings in the literature [13, 29, 30]. 
Yilmaz et  al. reported that omentin levels increased sig-
nificantly in patients with nonalcoholic fatty liver disease 
[13]. Another study showed that insulin-sensitizing drugs 
reduced omentin levels in newly diagnosed patients with 
diabetes [31]. Also, in a study of asymptomatic prepuber-
tal children, higher serum omentin was associated with 
a less favorable metabolic profile including features such 
as insulin resistance and high BP [29]. Kilic et al. reported 
that plasma omentin levels did not differ between MS 
patients and control subjects, and in all subjects, omentin 
was positively correlated with triglyceride levels and nega-
tively correlated with HDL-C levels [30]. They explained 
that one difference among studies was the technique used 
to determine omentin levels. Conversely, another specu-
lation is that omentin may pre-date and worsen diabetic 
CAN, although this is contrary to the known role of 
omentin as a beneficial adipokine.
In this study, we examined the relationship between 
omentin and baPWV and ABI as parameters of 
macrovascular disease. Our study showed that mean 
baPWV increased significantly and progressively across 
the omentin tertiles and was significantly positively cor-
related with omentin level. These results are consistent 
with those of previous studies. To date, only two stud-
ies by Yoo et  al. have reported a relationship between 
serum omentin and arterial stiffening in T2DM. The 
authors cross-sectionally investigated the association 
between omentin and arterial stiffness by baPWV in 60 
patients with T2DM [24]. Subjects in the highest tertile 
of serum omentin exhibited the most significant detri-
mental baPWV values of all the tertiles. Since then, they 
performed prospective study to investigate the impact 
of omentin levels on arterial stiffening in 120 patients 
with T2DM [32]. They observed a much greater increase 
in serum omentin levels in the group that experienced 
arterial stiffening. The authors speculated that this para-
doxical increase in serum omentin levels in subjects in 
the increased baPWV group might be a mechanism to 
compensate for the aggravation of arterial stiffness. In 
addition, several studies have demonstrated a close rela-
tionship between orthostatic hypotension, one of CAN 
components and arterial stiffness [33, 34]. Therefore, it 
is possible to speculate that the presence of orthostatic 
hypotension may contribute to an association of serum 
omentin with baWV. In our study, four subjects applied 
to borderline group as a difference of 11–19  mmHg in 
SBP between lying down and after standing up, whereas 
one subject applied to orthostatic hypotension as a dif-
ference of more than 20 mmHg. In this study, the prev-
alence of orthostatic hypotension was very low. The 
contribution of orthostatic hypotension regarding on the 
association of serum omentin and baPWV may be incon-
clusive at least in our study. Further prospective studies 
with larger number of patients having various severity of 
complications to clarify the role of orthostatic hypoten-
sion are needed.
In our present study, significant associations of 
HOMA-IR or glucose parameters with serum omentin 
were not detected. Consistent with our study, Hossein-
nezhad et  al. reported that a significant associations of 
omentin with HOMA-IR and glucose metabolism were 
not detected in 81 women [35].
The strengths of the present study are that it is the first 
report on the association of serum omentin and all micro-
vascular complications, including CAN, in patients with 
T2DM. Nevertheless, this study has several limitations. 
This was a cross-sectional study, which therefore could 
not determine causal relationships between omentin lev-
els, arterial stiffness, and diabetic vascular complications. 
In addition, there was a potential selection bias because 
our study population consisted of individuals who had 
received overall diabetic complication studies; therefore, 
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the characteristics of the present study population may 
have differed substantially from those of other popula-
tions that did not participate in complication studies.
Conclusions
In conclusion, this present study suggests that serum 
omentin levels independently associate with CAN in 
patients with T2DM. In addition, elevated serum omen-
tin levels seem to be associated with arterial stiffness. 
Future prospective studies with a larger sample size are 
required to establish a direct relationship between serum 
omentin levels and the development or severity of CAN.
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